| アブストラクト | OBJECTIVE: Lecanemab, a humanized immunoglobulin monoclonal antibody, has been approved for the treatment of Alzheimer's disease (AD). Although clinical trials have demonstrated its favorable safety profile, real-world studies are crucial for identifying rare adverse events (AEs) and evaluating post-marketing safety. This study aimed to evaluate the safety of lecanemab by combining a clinical prospective, observational case cohort with data from the FAERS database, thereby providing a robust basis for the identification of potential safety signals. METHODS: A prospective and observational study was conducted on patients with mild-to-moderate AD receiving lecanemab treatment at a tertiary medical center in China from July 2024 to February 2026. Extracted data included demographic characteristics, time to onset of AEs, and clinical symptoms. Exposure-adjusted incidence rates were calculated per 100 patient-years (PYs). Disproportionality analysis was performed using the US Food and Drug Administration Adverse Event Reporting System (FAERS), and safety signals for AEs observed in the cohort were evaluated utilizing reporting odds ratios (RORs) and proportional reporting ratios (PRRs). Additionally, data from these two real-world sources were compared and cross-validated. RESULTS: The single-center prospective study enrolled a total of 91 patients. The median duration of lecanemab treatment was 185 days. Thirteen AEs were recorded (56.48/100 PYs), with the most frequent being amyloid-related imaging abnormalities-hemosiderin deposition (ARIA-H; defined as microhemorrhages and hemosiderin deposition) (12.39/100 PYs) and infusion-related reactions (IRRs) (8.85/100 PYs). In the FAERS database, the most frequently reported preferred terms (PTs) included headache, amyloid-related imaging abnormalities-edema/effusion (ARIA-E), ARIA-H, and IRRs. The majority of AEs occurred within the first 1-2 months after initiating lecanemab treatment (n = 393, 45.65%). Furthermore, FAERS analysis revealed a potential safety signal for cerebral infarction. However, this finding must be interpreted cautiously due to the lack of complete data on traditional stroke risk factors and concomitant antithrombotic use in spontaneous reports. CONCLUSION: In this single-center prospective observational study, lecanemab demonstrated a generally favorable safety profile. Patients with AD aged 65 to 85 years represent a high-risk demographic for AEs. Particular clinical vigilance is required regarding the occurrence of AEs within the first two months of lecanemab initiation. Notably, ARIA (including both ARIA-E and ARIA-H) can occur at any phase during the treatment course. |
|---|
| ジャーナル名 | Frontiers in neuroinformatics |
|---|
| Pubmed追加日 | 2026/10/17 |
|---|
| 投稿者 | Ji, Haixia; Yang, Yang; Wu, Xingqi; Bao, Erhao |
|---|
| 組織名 | Department of Neurology, The First Affiliated Hospital of Anhui Medical;University, Hefei, Anhui, China.;Department of Traditional Chinese Medicine, Sichuan Provincial People's Hospital;East Sichuan Hospital & Dazhou First People's Hospital, Dazhou, Sichuan, China.;Department of Urology, Sichuan Provincial People's Hospital East Sichuan & Dazhou;First People's Hospital, Dazhou City Traditional Chinese Medicine Industry;Incubation Center, Dazhou City Traditional Chinese Medicine Research Center,;Dazhou, Sichuan, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42890205/ |
|---|
